It’s not a matter of if, but rather when, the next flu pandemic will occur, so preparations are being made now to save lives and reduce costs.
Vaccine shortages do occur, but plans are in place to help mitigate them and to lessen their impact on both public and private sectors.
With the cost of medications in hospitals, outpatient areas, physician offices and at home surging at an unprecedented rate, emphasis is on drug pricing reform and cost management.
The 340B program is under close scrutiny, with stakeholders reviewing its policies, procedures and discounts, among other issues.
Many QI programs are subject to missteps, but approaches that implement QI essentials can bring healthcare closer to realizing its potential.
The philosophical shift in healthcare payment reform is moving away from fee-for-service to a variety of models, including bundled payments that pay for value.
Meeting the future healthcare needs of aging baby boomers will require tackling the rise of chronic illness, addressing the impact of Alzheimer’s disease and reinventing care models to address the needs of a graying America.
The U.S. market for IVIG continues to grow well over 5 percent annually. What is driving the market demand?
Recently published proposed changes to the outpatient prospective payment system affect drugs and biologicals. Here are suggestions for how to implement
best practices.
